Fresenius Medical Care
| Company type | KGaA with Aktiengesellschaft as partner with unlimited liability |
|---|---|
| FWB: FME FWB: FMEA (ADR) OTC Pink Current: FMCQF NYSE: FMS (ADR) DAX component (FME) | |
| ISIN | DE0005785802 US3580291066 |
| Industry | Health care |
| Founded | 1996 |
| Headquarters | Bad Homburg vor der Höhe, Germany
|
Key people | Helen Giza (CEO, Chair of the management board and acting CFO) Dieter Schenk (Chairman of the supervisory board) |
| Products | Dialysis products and services, Therapeutic Apheresis Products |
| Revenue | €19.40 billion (2022) |
| €1.51 billion (2022) | |
| €0.67 billion (2022) | |
| Total assets | €34,367 million (2021) |
| Total equity | €13,979 million (2021) |
| Owner | Fresenius (32%) |
Number of employees | 128,000 (2022) |
| Website | www |
| Footnotes / references | |
Fresenius Medical Care AG & Co. KGaA is an American-German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
The company is on the Best Employers List published by Forbes.